An uncompromising commitment to freedom of movement
LONDON, March 7, 2023 /PRNewswire/ -- Smith+Nephew (LSE:
SN, NYSE: SNN), the global medical technology company, today
unveils "Precision in Motion", a franchise-level value proposition
spanning its Robotics, Knee, and Hip portfolios within the
Orthopaedics business. It underscores Smith+Nephew's promise to
deliver an uncompromising commitment to freedom of movement by
focusing on three key elements– personalizing surgery, advancing
efficiency, and optimizing performance.
![Smith & Nephew logo. Smith & Nephew logo.](https://mma.prnewswire.com/media/3924/Smith_Nephew_Logo.jpg)
"Precision speaks directly to our technology business. The
ability to deliver accuracy and precision is at the core of our
robotics platform, while 'in motion' activates the implant
franchises. The combination of these portfolios will enable
surgeons to best manage patient needs," noted Randy Kilburn, EVP and GM of Smith+Nephew
Orthopaedics. "Precision in Motion embodies the strategic direction
of the Orthopaedic business. Focusing the portfolio in this manner
will showcase current products and future investments aligned to
customer needs. We have the ability now to personalize surgery,
advance efficiency, and optimize performance with our implant and
enabling technology portfolios".
Personalizing Surgery
By combining technologies like
RI.KNEE and RI.HIP NAVIGATION with JOURNEY™ II
Total Knee Arthroplasty, POLAR3™ Total Hip Solution, and
the OR3O™ Dual Mobility Hip System, Smith+Nephew
delivers solutions that give surgeons the ability to place the
implant based on individual patient anatomy.
"Combining an implant that was designed to restore shape,
position, and motion of the normal knee, with our new Digital
Tensioner will allow surgeons to collect individual knee tension –
this will be a game changer for us", stated Michelle Paknad, VP,
Global Marketing – Robotics and Digital Technologies at
Smith+Nephew.
Advancing Efficiency
"With so much emphasis on
efficiency, we are thrilled to help customers make the complex as
simple as possible," noted Tim
Bourne, VP, Global Marketing – Knees at
Smith+Nephew. We are proud to be the only company in the US to
offer a fully cementless partial knee with the
ENGAGE™ Cementless Partial Knee System.
Smith+Nephew now offers the first and only robotic revision
indication in the US with RI.KNEE ROBOTICS – combining the
CORI™ Surgical System and
LEGION™ RK System with
OXINIUM™ Technology. A robotics solution that
provides surgeons with precision technology, enabling them to
manage bony defects and joint line restoration in these difficult
cases.
Optimizing Performance
"Smith+Nephew is optimizing
performance by providing innovative, patient-centric, implant and
technology solutions that work together to solve the clinical
problems our customers face", stated Simran
Sabharwal, VP, Global Marketing – Hips at Smith+Nephew. "Hip
instability is the most common cause for revision, after infection.
We are the only company that can offer a CoCr-free modular dual
mobility solution, the OR3O™ Dual Mobility System,
building on the proven performance of our
OXINIUM™ Technology."
To learn more about the latest advancements in orthopaedic
reconstruction and robotics, please stop by the Smith+Nephew booth
(#2021) during AAOS 2023.
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology company focused on the repair, regeneration and
replacement of soft and hard tissue. We exist to restore people's
bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 19,000
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product
portfolio, and the invention and application of new technologies
across our three global franchises of Orthopaedics, Sports
Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856,
we now operate in more than 100 countries, and generated annual
sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE: SN, NYSE: SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID-19, such as the depth and longevity
of its impact, government actions and other restrictive measures
taken in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID-19; economic and financial conditions in the markets we
serve, especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID-19);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID-19);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™Trademark of Smith+Nephew. Certain marks
registered US Patent and Trademark Office.
Logo -
https://mma.prnewswire.com/media/3924/Smith_Nephew_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/smithnephew-unveils-precision-in-motion-for-its-orthopaedics-arthroplasty-portfolio-at-aaos-2023-annual-meeting-301763781.html